United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - doxorubicin hydrochloride (unii: 82f2g7bl4e) (doxorubicin - unii:80168379ag) - doxorubicin hydrochloride 2 mg in 1 ml - adriamycin (doxorubicin hcl) injection, usp and adriamycin (doxorubicin hcl) for injection, usp is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer [see clinical studies (14.1)]. doxorubicin is indicated for the treatment of - acute lymphoblastic leukemia - acute myeloblastic leukemia - hodgkin lymphoma - non-hodgkin lymphoma (nhl) - metastatic breast cancer - metastatic wilms’ tumor - metastatic neuroblastoma - metastatic soft tissue sarcoma - metastatic bone sarcoma - metastatic ovarian carcinoma doxorubicin is contraindicated in patients with: - severe myocardial insufficiency [see warnings and precautions (5.1)] - recent (occurring within the past 4 to 6 weeks) myocardial infarction [see warnings and precautions (5.1)] - severe persistent drug-induced myelosuppression [see warnings and precautions (5.4)] - severe hepatic impairment (defined as child pugh class c or serum bilirubin level gr

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - doxorubicin hydrochloride (unii: 82f2g7bl4e) (doxorubicin - unii:80168379ag) - doxorubicin hydrochloride 2 mg in 1 ml - adriamycin (doxorubicin hcl) for injection, usp is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer [see clinical studies (14.1)]. doxorubicin is indicated for the treatment of - acute lymphoblastic leukemia - acute myeloblastic leukemia - hodgkin lymphoma - non-hodgkin lymphoma (nhl) - metastatic breast cancer - metastatic wilms’ tumor - metastatic neuroblastoma - metastatic soft tissue sarcoma - metastatic bone sarcoma - metastatic ovarian carcinoma doxorubicin is contraindicated in patients with: - severe myocardial insufficiency [see warnings and precautions (5.1)] - recent (occurring within the past 4 to 6 weeks) myocardial infarction [see warnings and precautions (5.1)] - severe persistent drug-induced myelosuppression [see warnings and precautions (5.4)] severe hepatic impairment (defined as child pugh class c or serum bilirubin level greater than 5 mg/dl) [see warnings and precautions

Kenya - English - Pharmacy and Poisons Board

doxorubicin hcl 50mg injection - injection - doxorubicin hcl 50mg injection - doxorubicin

Kenya - English - Pharmacy and Poisons Board

korea united pharma.inc c/o surgilinks ltd surgilinks building, mombasa road - doxorubicin hcl 10mg - injection - doxorubicin hcl 10mg - doxorubicin

Kenya - English - Pharmacy and Poisons Board

korea united pharma. inc c/o surgilinks ltd surgilinks building, mombasa road - doxorubicin hcl - injection - doxorubicin hcl 50mg - doxorubicin

Singapore - English - HSA (Health Sciences Authority)

shoei universal corporation pte ltd - doxorubicin hcl eqv doxorubicin - injection, powder, for solution - 10 mg/vial - doxorubicin hcl eqv doxorubicin 10 mg/vial

Singapore - English - HSA (Health Sciences Authority)

shoei universal corporation pte ltd - doxorubicin hcl eqv doxorubicin - injection, powder, for solution - 50 mg/vial - doxorubicin hcl eqv doxorubicin 50 mg/vial

Canada - English - Health Canada

david bull laboratories (pty) ltd. - doxorubicin hydrochloride - powder for solution - 150mg - doxorubicin hydrochloride 150mg - antineoplastic agents

Canada - English - Health Canada

david bull laboratories (pty) ltd. - doxorubicin hydrochloride - powder for solution - 50mg - doxorubicin hydrochloride 50mg - antineoplastic agents

Canada - English - Health Canada

david bull laboratories (pty) ltd. - doxorubicin hydrochloride - powder for solution - 10mg - doxorubicin hydrochloride 10mg - antineoplastic agents